You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Sodium Glucose Co-Transporter 2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)

Not yet recruiting
  • Atrial Fibrillation
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Rhythm control and anticoagulation
  • (no location specified)
Aug 14, 2023

Aortic Valve Stenosis Trial in Strasbourg (Myocardium biopsy)

Not yet recruiting
  • Aortic Valve Stenosis
  • Myocardium biopsy
  • Strasbourg, France
    Hôpitaux Universitaires de Strasbourg
Apr 13, 2023

Healthy Volunteers Trial run by the NIDDK (Placebo, Canagliflozin)

Completed
  • Healthy Volunteers
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in

Not yet recruiting
  • Diabetes Mellitus, Type 2
  • Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
  • (no location specified)
May 22, 2023

Heart Attack, Enlarged Heart Trial in Minneapolis (Dapagliflozin, Placebo)

Recruiting
  • Heart Attack
  • Enlarged Heart
  • Minneapolis, Minnesota
    Minneapolis Heart Institute Foundation
Aug 4, 2022

Acute Pancreatitis in Type 2 Diabetes Mellitus Treated With

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • empagliflozin
  • Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim International GmbH
Aug 19, 2022

SGLT2-I Use in DFUD: a Delphi Study

Not yet recruiting
  • Diabetic Foot Ulcer
  • eDelphi method
  • (no location specified)
Aug 14, 2023

Heart Failure With Reduced Ejection Fraction Trial in Chicago (SGLT2i, No SGLT2i)

Recruiting
  • Heart Failure With Reduced Ejection Fraction
  • Chicago, Illinois
    University of Chicago
Nov 11, 2022

Lupus Nephritis Trial in Alexandria (Dapagliflozin 10mg Tab orally once daily)

Not yet recruiting
  • Lupus Nephritis
  • Dapagliflozin 10mg Tab orally once daily
  • Alexandria, Egypt
    Ain Shams University
Oct 27, 2023

Obesity, Type 2 Diabetes, Sodium-glucose Co-transporter-2 Inhibitor Trial (Henagliflozin, Metformin)

Not yet recruiting
  • Obesity
  • +4 more
  • (no location specified)
Sep 27, 2023

SGLT-2 Inhibitors in T2DM and Moderate to Severe Liver Fibrosis

Completed
  • Type2diabetes
    • New Delhi, Delhi, India
      Fortis CDOC Hospital
    Jul 14, 2023

    SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac

    Recruiting
    • Coronary Artery Disease
    • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
    • Shah Alam, Selangor, Malaysia
      Institute for Clinical Research, National Institutes of Health,
    Nov 9, 2023

    Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)

    Not yet recruiting
    • Kidney Transplant Recipients
    • Dapagliflozin 10 MG
    • Semaglutide, 1.0 mg/mL
    • Toronto, Ontario, Canada
      Toronto General Hospital
    Jul 6, 2023

    Obesity, Dapagliflozin Adverse Reaction, Weight Loss Trial (Dapagliflozin 10mg Tab)

    Not yet recruiting
    • Obesity
    • +3 more
    • Dapagliflozin 10mg Tab
    • (no location specified)
    Aug 14, 2023

    Acute Decompensated Heart Failure Trial in Chicago (SGLT2i, No SGLT2i)

    Not yet recruiting
    • Acute Decompensated Heart Failure
    • Chicago, Illinois
      University of Chicago
    Jun 10, 2022

    Chronic Kidney Diseases, Bone Diseases, Metabolic Trial in Mansoura (Dapagliflozin 10mg Tab, Placebo)

    Active, not recruiting
    • Chronic Kidney Diseases
    • Bone Diseases, Metabolic
    • Dapagliflozin 10mg Tab
    • Placebo
    • Mansoura, Aldakahliya, Egypt
      Urology and Nephrology center, Mansoura University
    Feb 16, 2023

    Myocardial Ischemia Trial (Dapagliflozin 10mg Tab, Placebo)

    Not yet recruiting
    • Myocardial Ischemia
    • Dapagliflozin 10mg Tab
    • Placebo
    • (no location specified)
    Feb 27, 2023

    Metabolic Associated Fatty Liver Disease Trial (dapagliflozin (Forxiga))

    Not yet recruiting
    • Metabolic Associated Fatty Liver Disease
    • dapagliflozin (Forxiga)
    • (no location specified)
    Mar 13, 2023

    Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors Trial in Toronto

    Not yet recruiting
    • Peritoneal Dialysis Complication
    • +4 more
    • Empagliflozin 25 MG
    • Toronto, Ontario, Canada
      Toronto General Hospital
    Jan 27, 2023

    Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor Trial in Netherlands (Dapagliflozin 10 MG Oral

    Not yet recruiting
    • Acute Kidney Injury
    • +2 more
    • Dapagliflozin 10 MG Oral Tablet [Farxiga]
    • Placebo
    • Amsterdam, Netherlands
    • +5 more
    Oct 18, 2022

    Empagliflozin in Type 2 Diabetes Population With and Without

    Not yet recruiting
    • Diabetes Mellitus, Type 2
    • Durham, North Carolina
      Duke Clinical Research Institute
    Aug 8, 2022

    Heart Failure, Sleep Disordered Breathing Trial in New York (Dapagliflozin, WatchPat)

    Not yet recruiting
    • Heart Failure
    • Sleep Disordered Breathing
    • New York, New York
      Vivian and Seymour Milstein Family Heart Center
    Mar 8, 2022

    Diabetic Nephropathy Type 2 Trial (Empagliflozin 25 MG, Enalapril Maleate 20 mg)

    Not yet recruiting
    • Diabetic Nephropathy Type 2
    • Empagliflozin 25 MG
    • Enalapril Maleate 20 mg
    • (no location specified)
    May 9, 2022

    Metabolic Syndrome, Type 2 Diabetes, Obesity Trial in Perth (Empagliflozin Oral Tablet [Jardiance], Placebo Oral Tablet)

    Recruiting
    • Metabolic Syndrome
    • +2 more
    • Empagliflozin Oral Tablet [Jardiance]
    • Placebo Oral Tablet
    • Perth, Western Australia, Australia
      Royal Perth Hospital
    Sep 23, 2021

    Type 2 Diabetes Trial in Seoul (TZD group, SGLT-2 group)

    Completed
    • Type 2 Diabetes Mellitus
    • TZD group
    • SGLT-2 group
    • Seoul, Korea, Republic of
      Division of Endocrinology and Metabolism, Department of Internal
    May 3, 2021